[ad_1] News and research before you hear CNBC and others. Claim your 2-week free trial StreetInsider Premium here. Eloxx Pharmaceuticals, Inc. ("Eloxx"), (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery …
Read More »
[ad_1] The main problem Regeneron (REGN) has enjoyed tremendous success in the stock market for almost 7 years since the approval of its mega-blockbuster drug for retinal diseases, Eylea, by the FDA. …
Read More »
[ad_1] After being assured that the Food and Drug Administration (FDA) and the Drug Enforcement Agency (DEA) accept GW Pharmaceuticals (NASDAQ: GWPH) plans to launch her marijuana-derived epilepsy drug, Epidiolex, in six …
Read More »
[ad_1] The Drug Enforcement Agency (DEA) awarded GW Pharmaceuticals& # 39; (NASDAQ: GWPH) epilepsy, Epidiolex, Appendix V status, its least restrictive classification. Decision allows GW Pharmaceuticals to start offering the only DEA-approved …
Read More »
[ad_1] Alexion Pharmaceuticals Inc. ALXN, + 0.37% Wednesday announced an agreement to purchase Syntimmune for a total value of $ 1.2 billion. Syntimmune is a clinical stage biotechnology company that is currently …
Read More »
[ad_1] GW Pharmaceuticals plc GWPH a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics from its patented cannabinoid product platform, with its US subsidiary Greenwich Biosciences, announced on …
Read More »